Hubei Jumpcan Pharmaceutical (600566) Q3 2026 earnings summary

Executive summary

• 9M revenue fell 7.50% YoY to RMB 3.637bn, while net income attributable to shareholders rose 3.77% to RMB 1.061bn and adjusted net income rose 8.19% to RMB 929.7m.

• Q3 revenue increased 10.62% YoY to RMB 1.309bn; attributable net income declined 7.15% to RMB 276.8m, while adjusted net income grew 39.65% to RMB 333.2m.

• Production efficiency, lower raw-material costs and tighter selling-expense controls supported higher gross margin and resilient adjusted profitability.

Financial highlights

• 9M operating cash flow was RMB 990.1m, up 40.73% YoY, mainly due to lower other operating cash payments.

• 9M total profit was RMB 1.239bn, down 1.72% YoY; net profit was RMB 1.045bn, versus RMB 1.024bn a year earlier.

• Q3 adjusted net income increased 39.65% YoY, attributed primarily to stronger sales performance.

• Total assets were RMB 17.102bn at September 30, down 3.38% from year-end; parent-attributable equity was RMB 14.097bn, down 3.48%.

Outlook and guidance

• Core-product demand stabilization, full absorption of procurement-policy effects and new products entering growth phases are expected to support a broader, more diversified product portfolio.

• Continued R&D and commercialization of internally developed and partnered products are part of the product strategy, alongside maintaining coverage across hospitals, primary care and retail channels.